Vascular endothelial growth factor (VEGF) in astrocytic gliomas : a prognostic factor?
Survival in astrocytic gliomas is closely related to WHO tumor grade. Within one tumor grade, especially in grade II and III tumors, the clinical course is variable and can hardly be predicted by histological criteria. Neovascularization is a neuropathological hallmark in high grade gliomas and angi...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 1999-01, Vol.45 (2), p.117-125 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 125 |
|---|---|
| container_issue | 2 |
| container_start_page | 117 |
| container_title | Journal of neuro-oncology |
| container_volume | 45 |
| creator | OEHRING, R. D MILETIC, M VALTER, M. M PIETSCH, T NEUMANN, J FIMMERS, R SCHLEGEL, U |
| description | Survival in astrocytic gliomas is closely related to WHO tumor grade. Within one tumor grade, especially in grade II and III tumors, the clinical course is variable and can hardly be predicted by histological criteria. Neovascularization is a neuropathological hallmark in high grade gliomas and angiogenic factors may play an important role in malignant tumor progression. Therefore, 162 primary astrocytic gliomas (57 astrocytomas WHO grade II, 27 astrocytomas WHO grade III and 78 glioblastomas WHO grade IV) were investigated immunohistochemically for expression of vascular endothelial growth factor (VEGF), which is considered to represent the main angiogenic factor in astrocytic gliomas. Clinical data known to influence prognosis were documented. VEGF expression was found in 21 of 57 astrocytomas WHO grade II (36.8%), in 18 of 27 astrocytomas WHO grade III (66.7%) and in 50 of 78 glioblastomas (64.1%). A strong correlation between VEGF expression and survival was found within the whole study group, however, within one tumor grade no such correlation was obvious. In a multifactorial analysis VEGF expression was not found to be an independent prognostic factor in astrocytic gliomas. |
| doi_str_mv | 10.1023/A:1006333005563 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69476112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>416809601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-2d8fb50889b94dfcad38d0dfde560218db689446ad392dbed1feb9060b40cffa3</originalsourceid><addsrcrecordid>eNpd0M9LwzAUB_AgipvTszcJIqKH6kvSJo0XGUOnMPCiw1tJ82Pr6BpNWmT_vZVNBE8Pvnze4_FF6JTADQHKbsd3BIAzxgCyjLM9NCSZYIlggu2jIRAukkym7wN0FOMKAFLByCEaEBAiF1QM0Xyuou5qFbBtjG-Xtq5UjRfBf7VL7JRufcBX84fp4zWuGqxiG7zetJXGi7ryaxXxHVb4I_hF4-NPvF25P0YHTtXRnuzmCL09PrxOnpLZy_R5Mp4lmoFsE2pyV2aQ57KUqXFaGZYbMM7YjAMluSl5LtOU97mkprSGOFtK4FCmoJ1TbIQut3f7Fz47G9tiXUVt61o11nex4DIVnBDaw_N_cOW70PS_FZTITFDgokdnO9SVa2uKj1CtVdgUv3X14GIH-tZU7YJqdBX_HKM0ozn7BtcreMI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219572067</pqid></control><display><type>article</type><title>Vascular endothelial growth factor (VEGF) in astrocytic gliomas : a prognostic factor?</title><source>MEDLINE</source><source>SpringerLink</source><creator>OEHRING, R. D ; MILETIC, M ; VALTER, M. M ; PIETSCH, T ; NEUMANN, J ; FIMMERS, R ; SCHLEGEL, U</creator><creatorcontrib>OEHRING, R. D ; MILETIC, M ; VALTER, M. M ; PIETSCH, T ; NEUMANN, J ; FIMMERS, R ; SCHLEGEL, U</creatorcontrib><description>Survival in astrocytic gliomas is closely related to WHO tumor grade. Within one tumor grade, especially in grade II and III tumors, the clinical course is variable and can hardly be predicted by histological criteria. Neovascularization is a neuropathological hallmark in high grade gliomas and angiogenic factors may play an important role in malignant tumor progression. Therefore, 162 primary astrocytic gliomas (57 astrocytomas WHO grade II, 27 astrocytomas WHO grade III and 78 glioblastomas WHO grade IV) were investigated immunohistochemically for expression of vascular endothelial growth factor (VEGF), which is considered to represent the main angiogenic factor in astrocytic gliomas. Clinical data known to influence prognosis were documented. VEGF expression was found in 21 of 57 astrocytomas WHO grade II (36.8%), in 18 of 27 astrocytomas WHO grade III (66.7%) and in 50 of 78 glioblastomas (64.1%). A strong correlation between VEGF expression and survival was found within the whole study group, however, within one tumor grade no such correlation was obvious. In a multifactorial analysis VEGF expression was not found to be an independent prognostic factor in astrocytic gliomas.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1023/A:1006333005563</identifier><identifier>PMID: 10778727</identifier><identifier>CODEN: JNODD2</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Adult ; Astrocytoma - mortality ; Astrocytoma - pathology ; Astrocytoma - surgery ; Biological and medical sciences ; Blotting, Western ; Brain Neoplasms - mortality ; Brain Neoplasms - pathology ; Brain Neoplasms - surgery ; Endothelial Growth Factors - analysis ; Endothelial Growth Factors - genetics ; Female ; Gene Expression ; Glioblastoma - mortality ; Glioblastoma - pathology ; Glioblastoma - surgery ; Humans ; Immunohistochemistry ; Lymphokines - analysis ; Lymphokines - genetics ; Male ; Medical sciences ; Middle Aged ; Neurology ; Prognosis ; Retrospective Studies ; Survival Analysis ; Tumors of the nervous system. Phacomatoses ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors</subject><ispartof>Journal of neuro-oncology, 1999-01, Vol.45 (2), p.117-125</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Nov 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-2d8fb50889b94dfcad38d0dfde560218db689446ad392dbed1feb9060b40cffa3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1322528$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10778727$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OEHRING, R. D</creatorcontrib><creatorcontrib>MILETIC, M</creatorcontrib><creatorcontrib>VALTER, M. M</creatorcontrib><creatorcontrib>PIETSCH, T</creatorcontrib><creatorcontrib>NEUMANN, J</creatorcontrib><creatorcontrib>FIMMERS, R</creatorcontrib><creatorcontrib>SCHLEGEL, U</creatorcontrib><title>Vascular endothelial growth factor (VEGF) in astrocytic gliomas : a prognostic factor?</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><description>Survival in astrocytic gliomas is closely related to WHO tumor grade. Within one tumor grade, especially in grade II and III tumors, the clinical course is variable and can hardly be predicted by histological criteria. Neovascularization is a neuropathological hallmark in high grade gliomas and angiogenic factors may play an important role in malignant tumor progression. Therefore, 162 primary astrocytic gliomas (57 astrocytomas WHO grade II, 27 astrocytomas WHO grade III and 78 glioblastomas WHO grade IV) were investigated immunohistochemically for expression of vascular endothelial growth factor (VEGF), which is considered to represent the main angiogenic factor in astrocytic gliomas. Clinical data known to influence prognosis were documented. VEGF expression was found in 21 of 57 astrocytomas WHO grade II (36.8%), in 18 of 27 astrocytomas WHO grade III (66.7%) and in 50 of 78 glioblastomas (64.1%). A strong correlation between VEGF expression and survival was found within the whole study group, however, within one tumor grade no such correlation was obvious. In a multifactorial analysis VEGF expression was not found to be an independent prognostic factor in astrocytic gliomas.</description><subject>Adult</subject><subject>Astrocytoma - mortality</subject><subject>Astrocytoma - pathology</subject><subject>Astrocytoma - surgery</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - surgery</subject><subject>Endothelial Growth Factors - analysis</subject><subject>Endothelial Growth Factors - genetics</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Glioblastoma - mortality</subject><subject>Glioblastoma - pathology</subject><subject>Glioblastoma - surgery</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lymphokines - analysis</subject><subject>Lymphokines - genetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tumors of the nervous system. Phacomatoses</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Vascular Endothelial Growth Factors</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0M9LwzAUB_AgipvTszcJIqKH6kvSJo0XGUOnMPCiw1tJ82Pr6BpNWmT_vZVNBE8Pvnze4_FF6JTADQHKbsd3BIAzxgCyjLM9NCSZYIlggu2jIRAukkym7wN0FOMKAFLByCEaEBAiF1QM0Xyuou5qFbBtjG-Xtq5UjRfBf7VL7JRufcBX84fp4zWuGqxiG7zetJXGi7ryaxXxHVb4I_hF4-NPvF25P0YHTtXRnuzmCL09PrxOnpLZy_R5Mp4lmoFsE2pyV2aQ57KUqXFaGZYbMM7YjAMluSl5LtOU97mkprSGOFtK4FCmoJ1TbIQut3f7Fz47G9tiXUVt61o11nex4DIVnBDaw_N_cOW70PS_FZTITFDgokdnO9SVa2uKj1CtVdgUv3X14GIH-tZU7YJqdBX_HKM0ozn7BtcreMI</recordid><startdate>19990101</startdate><enddate>19990101</enddate><creator>OEHRING, R. D</creator><creator>MILETIC, M</creator><creator>VALTER, M. M</creator><creator>PIETSCH, T</creator><creator>NEUMANN, J</creator><creator>FIMMERS, R</creator><creator>SCHLEGEL, U</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19990101</creationdate><title>Vascular endothelial growth factor (VEGF) in astrocytic gliomas : a prognostic factor?</title><author>OEHRING, R. D ; MILETIC, M ; VALTER, M. M ; PIETSCH, T ; NEUMANN, J ; FIMMERS, R ; SCHLEGEL, U</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-2d8fb50889b94dfcad38d0dfde560218db689446ad392dbed1feb9060b40cffa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Astrocytoma - mortality</topic><topic>Astrocytoma - pathology</topic><topic>Astrocytoma - surgery</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - surgery</topic><topic>Endothelial Growth Factors - analysis</topic><topic>Endothelial Growth Factors - genetics</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Glioblastoma - mortality</topic><topic>Glioblastoma - pathology</topic><topic>Glioblastoma - surgery</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lymphokines - analysis</topic><topic>Lymphokines - genetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tumors of the nervous system. Phacomatoses</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Vascular Endothelial Growth Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OEHRING, R. D</creatorcontrib><creatorcontrib>MILETIC, M</creatorcontrib><creatorcontrib>VALTER, M. M</creatorcontrib><creatorcontrib>PIETSCH, T</creatorcontrib><creatorcontrib>NEUMANN, J</creatorcontrib><creatorcontrib>FIMMERS, R</creatorcontrib><creatorcontrib>SCHLEGEL, U</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OEHRING, R. D</au><au>MILETIC, M</au><au>VALTER, M. M</au><au>PIETSCH, T</au><au>NEUMANN, J</au><au>FIMMERS, R</au><au>SCHLEGEL, U</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vascular endothelial growth factor (VEGF) in astrocytic gliomas : a prognostic factor?</atitle><jtitle>Journal of neuro-oncology</jtitle><addtitle>J Neurooncol</addtitle><date>1999-01-01</date><risdate>1999</risdate><volume>45</volume><issue>2</issue><spage>117</spage><epage>125</epage><pages>117-125</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><coden>JNODD2</coden><abstract>Survival in astrocytic gliomas is closely related to WHO tumor grade. Within one tumor grade, especially in grade II and III tumors, the clinical course is variable and can hardly be predicted by histological criteria. Neovascularization is a neuropathological hallmark in high grade gliomas and angiogenic factors may play an important role in malignant tumor progression. Therefore, 162 primary astrocytic gliomas (57 astrocytomas WHO grade II, 27 astrocytomas WHO grade III and 78 glioblastomas WHO grade IV) were investigated immunohistochemically for expression of vascular endothelial growth factor (VEGF), which is considered to represent the main angiogenic factor in astrocytic gliomas. Clinical data known to influence prognosis were documented. VEGF expression was found in 21 of 57 astrocytomas WHO grade II (36.8%), in 18 of 27 astrocytomas WHO grade III (66.7%) and in 50 of 78 glioblastomas (64.1%). A strong correlation between VEGF expression and survival was found within the whole study group, however, within one tumor grade no such correlation was obvious. In a multifactorial analysis VEGF expression was not found to be an independent prognostic factor in astrocytic gliomas.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>10778727</pmid><doi>10.1023/A:1006333005563</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 1999-01, Vol.45 (2), p.117-125 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69476112 |
| source | MEDLINE; SpringerLink |
| subjects | Adult Astrocytoma - mortality Astrocytoma - pathology Astrocytoma - surgery Biological and medical sciences Blotting, Western Brain Neoplasms - mortality Brain Neoplasms - pathology Brain Neoplasms - surgery Endothelial Growth Factors - analysis Endothelial Growth Factors - genetics Female Gene Expression Glioblastoma - mortality Glioblastoma - pathology Glioblastoma - surgery Humans Immunohistochemistry Lymphokines - analysis Lymphokines - genetics Male Medical sciences Middle Aged Neurology Prognosis Retrospective Studies Survival Analysis Tumors of the nervous system. Phacomatoses Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors |
| title | Vascular endothelial growth factor (VEGF) in astrocytic gliomas : a prognostic factor? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A55%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vascular%20endothelial%20growth%20factor%20(VEGF)%20in%20astrocytic%20gliomas%20:%20a%20prognostic%20factor?&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=OEHRING,%20R.%20D&rft.date=1999-01-01&rft.volume=45&rft.issue=2&rft.spage=117&rft.epage=125&rft.pages=117-125&rft.issn=0167-594X&rft.eissn=1573-7373&rft.coden=JNODD2&rft_id=info:doi/10.1023/A:1006333005563&rft_dat=%3Cproquest_pubme%3E416809601%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219572067&rft_id=info:pmid/10778727&rfr_iscdi=true |